RedShiftBio has developed a Microfluidic Modulation Spectroscopy (MMS) platform that enables scientists to detect and monitor protein conformation and conduct label-free protein analysis. The company's tools combine laser, microfluidics, and analytical technologies to measure protein-based drug therapies, allowing scientists to detect previously undetectable changes in protein structural attributes critical to drug product efficacy and quality. RedShiftBio's proprietary life sciences platform provides ultra-sensitive and ultra-precise measurements of molecular structure, which are available to researchers in their fully-automated AQS³pro Analyzer. The company is led by an experienced management team and has a global network of sales, applications, service, and support teams to address all market needs.